New cell therapy targets tough leukemia
NCT ID NCT07336875
First seen Jan 17, 2026 · Last updated Jun 09, 2026 · Updated 26 times
Summary
This early-phase study tests a new type of immune cell therapy (CAR-ITNK cells) designed to attack two specific targets on leukemia cells. It is for adults aged 18 to 75 with acute myeloid leukemia that has returned or not responded to standard treatment. Participants receive a single infusion and are followed for three years to check safety and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.